{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:54:31Z","timestamp":1789181671246,"version":"build-2803163510"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41571-021-00474-4","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T17:27:43Z","timestamp":1613842063000},"page":"435-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-9404","authenticated-orcid":false,"given":"Dristhi","family":"Ragoonanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-608X","authenticated-orcid":false,"given":"Sajad J.","family":"Khazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Abdel-Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-9670","authenticated-orcid":false,"given":"David","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Haider","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney M.","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Schadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Gulbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basirat","family":"Shoberu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Mireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9936-9569","authenticated-orcid":false,"given":"Julie C.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Hingorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita D.","family":"Swinford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorela N.","family":"Hernandez Tejada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Auletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-3834","authenticated-orcid":false,"given":"Sung Won","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-0322","authenticated-orcid":false,"given":"Rajinder","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-4929","authenticated-orcid":false,"given":"Natalie","family":"Dailey Garnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-9674","authenticated-orcid":false,"given":"Kris M.","family":"Mahadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"474_CR1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1478951512001083","volume":"12","author":"S Palmer","year":"2014","unstructured":"Palmer, S., Patterson, P. & Thompson, K. A national approach to improving adolescent and young adult (AYA) oncology psychosocial care: the development of AYA-specific psychosocial assessment and care tools. Palliat. Support. Care 12, 183\u2013188 (2014).","journal-title":"Palliat. Support. Care"},{"key":"474_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45\u201363 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"474_CR3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR4","unstructured":"FDA. Highlights of Prescribing Information: KYMRIAH. https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Package-Insert---KYMRIAH.pdf (2018)."},{"key":"474_CR5","unstructured":"FDA. Highlights of Prescribing Information: YESCARTA. https:\/\/www.fda.gov\/media\/108377\/download (2020)."},{"key":"474_CR6","unstructured":"FDA. Highlights of Prescribing Information: TECARTUS. https:\/\/www.fda.gov\/media\/140409\/download (2020)."},{"key":"474_CR7","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"474_CR8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal. Transduct. Target. Ther. 4, 35 (2019).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"474_CR9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"LA Johnson","year":"2017","unstructured":"Johnson, L. A. & June, C. H. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 27, 38\u201358 (2017).","journal-title":"Cell Res."},{"key":"474_CR10","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/ijms20143586","volume":"20","author":"REM Baiden-Amissah","year":"2019","unstructured":"Baiden-Amissah, R. E. M. & Tuyaerts, S. Contribution of aging, obesity, and microbiota on tumor immunotherapy efficacy and toxicity. Int. J. Mol. Sci. 20, 3586 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"474_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella, M. & Maus, M. V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 14, 357\u2013362 (2016).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"474_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","volume":"35","author":"K Fousek","year":"2021","unstructured":"Fousek, K. et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 35, 75\u201389 (2021).","journal-title":"Leukemia"},{"key":"474_CR13","volume":"12","author":"B Gy\u00f6rgy","year":"2020","unstructured":"Gy\u00f6rgy, B. Bispecific CAR T cells have a dual grasp on tumors. Sci. Transl. Med. 12, eabf2636 (2020).","journal-title":"Sci. Transl. Med."},{"key":"474_CR14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"474_CR16","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885\u20131894 (2020).","journal-title":"Lancet"},{"key":"474_CR17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"474_CR18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/0008-5472.CAN-17-0576","volume":"78","author":"MC Scott","year":"2018","unstructured":"Scott, M. C. et al. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res. 78, 326\u2013337 (2018).","journal-title":"Cancer Res."},{"key":"474_CR19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","volume":"163","author":"A Serrels","year":"2015","unstructured":"Serrels, A. et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 163, 160\u2013173 (2015).","journal-title":"Cell"},{"key":"474_CR20","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676\u20131680 (1988).","journal-title":"N. Engl. J. Med."},{"key":"474_CR21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-med-112311-083918","volume":"64","author":"G Lizee","year":"2013","unstructured":"Lizee, G. et al. Harnessing the power of the immune system to target cancer. Annu. Rev. Med. 64, 71\u201390 (2013).","journal-title":"Annu. Rev. Med."},{"key":"474_CR22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri1842","volume":"6","author":"L Gattinoni","year":"2006","unstructured":"Gattinoni, L., Powell, D. J. Jr., Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383\u2013393 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"474_CR23","first-page":"353","volume":"7","author":"Z Wang","year":"2016","unstructured":"Wang, Z., Li, B., Ren, Y. & Ye, Z. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities. Front. Immunol. 7, 353 (2016).","journal-title":"Front. Immunol."},{"key":"474_CR24","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"474_CR25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850\u2013854 (2002).","journal-title":"Science"},{"key":"474_CR26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159\u20131166 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"474_CR27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst, M. R. et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9, 1022\u20131035 (2019).","journal-title":"Cancer Discov."},{"key":"474_CR28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet Oncol."},{"key":"474_CR29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216373","volume":"14","author":"M Olle Hurtado","year":"2019","unstructured":"Olle Hurtado, M. et al. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. PLoS ONE 14, e0216373 (2019).","journal-title":"PLoS ONE"},{"key":"474_CR30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fonc.2018.00044","volume":"8","author":"JE Mullinax","year":"2018","unstructured":"Mullinax, J. E. et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front. Oncol. 8, 44 (2018).","journal-title":"Front. Oncol."},{"key":"474_CR31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40425-019-0631-z","volume":"7","author":"Q Zhao","year":"2019","unstructured":"Zhao, Q. et al. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J. Immunother. Cancer 7, 154 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"474_CR32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","volume":"68","author":"LT Nguyen","year":"2019","unstructured":"Nguyen, L. T. et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol. Immunother. 68, 773\u2013785 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"474_CR33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdi226","volume":"16","author":"W Schwinger","year":"2005","unstructured":"Schwinger, W. et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann. Oncol. 16, 1199\u20131206 (2005).","journal-title":"Ann. Oncol."},{"key":"474_CR34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ophtha.2008.12.004","volume":"116","author":"S Yeh","year":"2009","unstructured":"Yeh, S. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116, 981\u2013989.e1 (2009).","journal-title":"Ophthalmology"},{"key":"474_CR35","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"474_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"474_CR37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"474_CR38","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","volume":"20","author":"T Chodon","year":"2014","unstructured":"Chodon, T. et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 20, 2457\u20132465 (2014).","journal-title":"Clin. Cancer Res."},{"key":"474_CR39","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara, I. et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130, 1985\u20131994 (2017).","journal-title":"Blood"},{"key":"474_CR40","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani, K., Rouce, R., Liu, E. & Shpall, E. Engineering natural killer cells for cancer immunotherapy. Mol. Ther. 25, 1769\u20131781 (2017).","journal-title":"Mol. Ther."},{"key":"474_CR41","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/neuonc\/noaa047","volume":"22","author":"S Khatua","year":"2020","unstructured":"Khatua, S. et al. Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 22, 1214\u20131225 (2020).","journal-title":"Neuro Oncol."},{"key":"474_CR42","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.4049\/jimmunol.167.4.2068","volume":"167","author":"V Screpanti","year":"2001","unstructured":"Screpanti, V., Wallin, R. P., Ljunggren, H. G. & Grandien, A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 167, 2068\u20132073 (2001).","journal-title":"J. Immunol."},{"key":"474_CR43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela, M. et al. Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 422, 107\u2013117 (2018).","journal-title":"Cancer Lett."},{"key":"474_CR44","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz, J. E. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955\u2013959 (2010).","journal-title":"J. Clin. Oncol."},{"key":"474_CR45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","volume":"7","author":"R Nguyen","year":"2019","unstructured":"Nguyen, R. et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J. Immunother. Cancer 7, 81 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"474_CR46","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-10-0735","volume":"16","author":"D Cho","year":"2010","unstructured":"Cho, D. et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res. 16, 3901\u20133909 (2010).","journal-title":"Clin. Cancer Res."},{"key":"474_CR47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2015.07.042","volume":"368","author":"L Fernandez","year":"2015","unstructured":"Fernandez, L. et al. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett. 368, 54\u201363 (2015).","journal-title":"Cancer Lett."},{"key":"474_CR48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","volume":"125","author":"NN Shah","year":"2015","unstructured":"Shah, N. N. et al. Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125, 784\u2013792 (2015).","journal-title":"Blood"},{"key":"474_CR49","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.exphem.2012.07.004","volume":"40","author":"A P\u00e9rez-Mart\u00ednez","year":"2012","unstructured":"P\u00e9rez-Mart\u00ednez, A. et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp. Hematol. 40, 882\u2013891.e1 (2012).","journal-title":"Exp. Hematol."},{"key":"474_CR50","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0837-8","volume":"21","author":"MS Kimpo","year":"2019","unstructured":"Kimpo, M. S., Oh, B. & Lee, S. The role of natural killer cells as a platform for immunotherapy in pediatric cancers. Curr. Oncol. Rep. 21, 93 (2019).","journal-title":"Curr. Oncol. Rep."},{"key":"474_CR51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman, C. J. et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).","journal-title":"PLoS ONE"},{"key":"474_CR52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","volume":"126","author":"MH Andersen","year":"2006","unstructured":"Andersen, M. H., Schrama, D., thor Straten, P. & Becker, J. C. Cytotoxic T cells. J. Invest. Dermatol. 126, 32\u201341 (2006).","journal-title":"J. Invest. Dermatol."},{"key":"474_CR53","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1073\/pnas.79.15.4718","volume":"79","author":"A Van Pel","year":"1982","unstructured":"Van Pel, A. & Boon, T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci. USA 79, 4718\u20134722 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"474_CR54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<323::AID-JCP2>3.0.CO;2-#","volume":"182","author":"C Castelli","year":"2000","unstructured":"Castelli, C. et al. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol. 182, 323\u2013331 (2000).","journal-title":"J. Cell. Physiol."},{"key":"474_CR55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-642-56352-2_15","volume":"159","author":"Z Liu","year":"2002","unstructured":"Liu, Z. et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent. Results Cancer Res. 159, 123\u2013133 (2002).","journal-title":"Recent. Results Cancer Res."},{"key":"474_CR56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop, S. et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J. Clin. Invest. 130, 733\u2013747 (2020).","journal-title":"J. Clin. Invest."},{"key":"474_CR57","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","volume":"115","author":"A Moosmann","year":"2010","unstructured":"Moosmann, A. et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115, 2960\u20132970 (2010).","journal-title":"Blood"},{"key":"474_CR58","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.bbmt.2019.12.444","volume":"26","author":"SE Prockop","year":"2020","unstructured":"Prockop, S. E. et al. A multicenter, open label, phase 3 study of tabelecleucel for solid organ transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disorder (EBV+PTLD) after failure of rituximab or rituximab and chemotherapy (ALLELE) [abstract]. Biol. Blood Marrow Transpl. 26, S274 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR59","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.bbmt.2019.12.228","volume":"26","author":"SE Prockop","year":"2020","unstructured":"Prockop, S. E. et al. Long-term outcomes of patients with epstein-barr virus-driven post-transplant lymphoproliferative disease following solid organ transplant or allogeneic hematopoietic cell transplant treated with tabelecleucel in a multicenter expanded access program study [abstract]. Biol. Blood Marrow Transpl. 26, S61\u2013S62 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR60","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","volume":"200","author":"CM Bollard","year":"2004","unstructured":"Bollard, C. M. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+Hodgkin\u2019s disease. J. Exp. Med. 200, 1623\u20131633 (2004).","journal-title":"J. Exp. Med."},{"key":"474_CR61","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof, K. C. et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898\u20131904 (2005).","journal-title":"Blood"},{"key":"474_CR62","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-0296","volume":"74","author":"A Schuessler","year":"2014","unstructured":"Schuessler, A. et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74, 3466\u20133476 (2014).","journal-title":"Cancer Res."},{"key":"474_CR63","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113\u20135123 (2013).","journal-title":"Blood"},{"key":"474_CR64","first-page":"427","volume":"391","author":"S Gottschalk","year":"2015","unstructured":"Gottschalk, S. & Rooney, C. M. Adoptive T-cell immunotherapy. Curr. Top. Microbiol. Immunol. 391, 427\u2013454 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"474_CR65","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu, M. et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 379, 1443\u20131451 (2018).","journal-title":"N. Engl. J. Med."},{"key":"474_CR66","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/ejh.12848","volume":"98","author":"OM Pello","year":"2017","unstructured":"Pello, O. M. et al. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur. J. Haematol. 98, 632\u2013634 (2017).","journal-title":"Eur. J. Haematol."},{"key":"474_CR67","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290\u2013296 (2015).","journal-title":"Immunol. Cell Biol."},{"key":"474_CR68","unstructured":"FDA. Highlights of Prescribing Information: Blincyto. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf (2018)."},{"key":"474_CR69","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767\u20131778 (2016).","journal-title":"N. Engl. J. Med."},{"key":"474_CR70","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/imcb.12054","volume":"96","author":"SM Toor","year":"2018","unstructured":"Toor, S. M. & Elkord, E. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. Immunol. Cell Biol. 96, 888\u2013897 (2018).","journal-title":"Immunol. Cell Biol."},{"key":"474_CR71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29\u201339 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"474_CR72","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"474_CR73","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant, M. S. et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin. Cancer Res. 22, 1364\u20131370 (2016).","journal-title":"Clin. Cancer Res."},{"key":"474_CR74","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejca.2017.09.032","volume":"86","author":"B Geoerger","year":"2017","unstructured":"Geoerger, B. et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur. J. Cancer 86, 358\u2013363 (2017).","journal-title":"Eur. J. Cancer"},{"key":"474_CR75","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis, K. L. et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 541\u2013550 (2020).","journal-title":"Lancet Oncol."},{"key":"474_CR76","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182\u20131191 (2017).","journal-title":"Lancet Oncol."},{"key":"474_CR77","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773\u2013779 (2018).","journal-title":"J. Clin. Oncol."},{"key":"474_CR78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger, B. et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 121\u2013133 (2020).","journal-title":"Lancet Oncol."},{"key":"474_CR79","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21, 655\u2013663 (2020).","journal-title":"Lancet Oncol."},{"key":"474_CR80","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","volume":"21","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe, A. et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 21, 1057\u20131065 (2020).","journal-title":"Lancet Oncol."},{"key":"474_CR81","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"474_CR82","first-page":"97","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh, A. K. et al. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC 2, 97\u2013109 (2020).","journal-title":"JACC"},{"key":"474_CR83","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng, Y. et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin. Cancer Res. 19, 3977\u20133986 (2013).","journal-title":"Clin. Cancer Res."},{"key":"474_CR84","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1297\/cpe.28.59","volume":"28","author":"K Ihara","year":"2019","unstructured":"Ihara, K. Immune checkpoint inhibitor therapy for pediatric cancers: a mini review of endocrine adverse events. Clin. Pediatr. Endocrinol. 28, 59\u201368 (2019).","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"474_CR85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"474_CR86","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714\u20131768 (2018).","journal-title":"J. Clin. Oncol."},{"key":"474_CR87","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"474_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13569","author":"M Queudeville","year":"2020","unstructured":"Queudeville, M. et al. Blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Eur. J. Haematol. https:\/\/doi.org\/10.1111\/ejh.13569 (2020).","journal-title":"Eur. J. Haematol."},{"key":"474_CR89","first-page":"S862","volume":"122","author":"MD Berg","year":"2010","unstructured":"Berg, M. D. et al. Part 13: Pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122, S862\u2013S875 (2010).","journal-title":"Circulation"},{"key":"474_CR90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","volume":"48","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez, C. et al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit. Care Med. 48, 10\u201321 (2020).","journal-title":"Crit. Care Med."},{"key":"474_CR91","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald, J. C. et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 45, e124\u2013e131 (2017).","journal-title":"Crit. Care Med."},{"key":"474_CR92","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12098-019-03096-y","volume":"87","author":"JP Roy","year":"2020","unstructured":"Roy, J. P. & Devarajan, P. Acute kidney injury: diagnosis and management. Indian J. Pediatr. 87, 600\u2013607 (2020).","journal-title":"Indian J. Pediatr."},{"key":"474_CR93","doi-asserted-by":"crossref","unstructured":"Fragasso, T., Ricci, Z. & Goldstein, S. L. in Contributions to Nephrology (eds Ding, X., Rosner, M. H. & Ronco, C.) 113\u2013126 (Karger, 2018). [Series Ed. Ronco, C. Acute Kidney Injury - Basic Research and Clinical Practice Vol. 193]","DOI":"10.1159\/000484968"},{"key":"474_CR94","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ndt\/gfv457","volume":"31","author":"S Menon","year":"2016","unstructured":"Menon, S. et al. Urinary biomarker incorporation into the renal angina index early in intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort study. Nephrol. Dial. Transpl. 31, 586\u2013594 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"474_CR95","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000071","volume":"2","author":"G Bottari","year":"2020","unstructured":"Bottari, G. et al. Multimodal therapeutic approach of cytokine release syndrome developing in a child given chimeric antigen receptor-modified T cell infusion. Crit. Care Explor. 2, e0071 (2020).","journal-title":"Crit. Care Explor."},{"key":"474_CR96","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","volume":"26","author":"V Gutgarts","year":"2020","unstructured":"Gutgarts, V. et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol. Blood Marrow Transpl. 26, 1071\u20131076 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta, S. et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am. J. Kidney Dis. 76, 63\u201371 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"474_CR98","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcrc.2020.04.008","volume":"58","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez, C. et al. The chimeric antigen receptor\u2013intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J. Crit. Care 58, 58\u201364 (2020).","journal-title":"J. Crit. Care"},{"key":"474_CR99","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1097\/01.CCM.0000239119.57544.0C","volume":"34","author":"MJ Dubois","year":"2006","unstructured":"Dubois, M. J. et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit. Care Med. 34, 2536\u20132540 (2006).","journal-title":"Crit. Care Med."},{"key":"474_CR100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00134-018-5075-2","volume":"44","author":"G Hariri","year":"2018","unstructured":"Hariri, G. et al. Albumin infusion improves endothelial function in septic shock patients: a pilot study. Intensive Care Med. 44, 669\u2013671 (2018).","journal-title":"Intensive Care Med."},{"issue":"Suppl. 1","key":"474_CR101","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1182\/blood-2018-99-117602","volume":"132","author":"Y Hu","year":"2018","unstructured":"Hu, Y., Feng, J., Shao, M. & Huang, H. Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy [abstract]. Blood 132 (Suppl. 1), 5204 (2018).","journal-title":"Blood"},{"key":"474_CR102","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-014-0029-5","volume":"4","author":"C Milesi","year":"2014","unstructured":"Milesi, C. et al. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann. Intensive Care 4, 29 (2014).","journal-title":"Ann. Intensive Care"},{"key":"474_CR103","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.rmed.2009.04.007","volume":"103","author":"K Dysart","year":"2009","unstructured":"Dysart, K., Miller, T. L., Wolfson, M. R. & Shaffer, T. H. Research in high flow therapy: mechanisms of action. Respir. Med. 103, 1400\u20131405 (2009).","journal-title":"Respir. Med."},{"key":"474_CR104","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/resp.12290","volume":"19","author":"CF McDonald","year":"2014","unstructured":"McDonald, C. F. Low-flow oxygen: how much is your patient really getting? Respirology 19, 469\u2013470 (2014).","journal-title":"Respirology"},{"key":"474_CR105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3345\/kjp.2019.00626","volume":"63","author":"JW Kwon","year":"2020","unstructured":"Kwon, J. W. High-flow nasal cannula oxygen therapy in children: a clinical review. Clin. Exp. Pediatr. 63, 3\u20137 (2020).","journal-title":"Clin. Exp. Pediatr."},{"key":"474_CR106","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/archdischild-2014-306590","volume":"100","author":"FA Hutchings","year":"2015","unstructured":"Hutchings, F. A., Hilliard, T. N. & Davis, P. J. Heated humidified high-flow nasal cannula therapy in children. Arch. Dis. Child. 100, 571\u2013575 (2015).","journal-title":"Arch. Dis. Child."},{"key":"474_CR107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2017.06.006","volume":"189","author":"T Weiler","year":"2017","unstructured":"Weiler, T. et al. The relationship between high flow nasal cannula flow rate and effort of breathing in children. J. Pediatr. 189, 66\u201371.e3 (2017).","journal-title":"J. Pediatr."},{"key":"474_CR108","first-page":"24","volume":"20","author":"SL Morley","year":"2016","unstructured":"Morley, S. L. Non-invasive ventilation in paediatric critical care. Paediatr. Respir. Rev. 20, 24\u201331 (2016).","journal-title":"Paediatr. Respir. Rev."},{"key":"474_CR109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/PCC.0000000000001805","volume":"20","author":"JV Morris","year":"2019","unstructured":"Morris, J. V., Kapetanstrataki, M., Parslow, R. C., Davis, P. J. & Ramnarayan, P. Patterns of use of heated humidified high-flow nasal cannula therapy in PICUs in the United Kingdom and Republic of Ireland. Pediatr. Crit. Care Med. 20, 223\u2013232 (2019).","journal-title":"Pediatr. Crit. Care Med."},{"key":"474_CR110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).","journal-title":"Sci. Transl. Med."},{"key":"474_CR111","unstructured":"Philip, B. RQR8: A universal safety switch for cellular therapies. Thesis, University College London (2015)."},{"key":"474_CR112","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner, R. A. et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134, 2149\u20132158 (2019).","journal-title":"Blood"},{"key":"474_CR113","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jcyt.2019.04.009","volume":"21","author":"S Kadauke","year":"2019","unstructured":"Kadauke, S. et al. Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019) [abstract]. Cytotherapy 21, e2\u2013e3 (2019).","journal-title":"Cytotherapy"},{"key":"474_CR114","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Yanez","year":"2019","unstructured":"Yanez, L., Sanchez-Escamilla, M. & Perales, M. A. CAR T cell toxicity: current management and future directions. Hemasphere 3, e186 (2019).","journal-title":"Hemasphere"},{"key":"474_CR115","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"474_CR116","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"474_CR117","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2352-3026(19)30201-7","volume":"7","author":"KM Mahadeo","year":"2020","unstructured":"Mahadeo, K. M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 7, e61\u2013e72 (2020).","journal-title":"Lancet Haematol."},{"key":"474_CR118","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust, J. et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann. Neurol. 86, 42\u201354 (2019).","journal-title":"Ann. Neurol."},{"key":"474_CR119","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"474_CR120","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"474_CR121","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M. & Cron, R. Q. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50, 417\u2013419 (2011).","journal-title":"Rheumatology"},{"key":"474_CR122","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter, J. I. et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124\u2013131 (2007).","journal-title":"Pediatr. Blood Cancer"},{"key":"474_CR123","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112\u20131121 (2016).","journal-title":"J. Clin. Oncol."},{"key":"474_CR124","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg, H. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18, 295\u2013304 (1974).","journal-title":"Transplantation"},{"key":"474_CR125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1705885","volume":"41","author":"D Jacobsohn","year":"2008","unstructured":"Jacobsohn, D. Acute graft-versus-host disease in children. Bone Marrow Transplant. 41, 215\u2013221 (2008).","journal-title":"Bone Marrow Transplant."},{"key":"474_CR126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris, A. C. et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transpl. 22, 4\u201310 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR127","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","volume":"11","author":"X Li","year":"2018","unstructured":"Li, X., Shao, C., Shi, Y. & Han, W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J. Hematol. Oncol. 11, 31 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"474_CR128","doi-asserted-by":"crossref","first-page":"109437","DOI":"10.1016\/j.biopha.2019.109437","volume":"120","author":"YH Liu","year":"2019","unstructured":"Liu, Y. H. et al. Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy. Biomed. Pharmacother. 120, 109437 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"474_CR129","volume":"97","author":"M Khan","year":"2018","unstructured":"Khan, M. et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine 97, e11936 (2018).","journal-title":"Medicine"},{"key":"474_CR130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11739-020-02295-2","volume":"15","author":"J de La Rochefoucauld","year":"2020","unstructured":"de La Rochefoucauld, J., Noel, N. & Lambotte, O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Intern. Emerg. Med. 15, 587\u2013598 (2020).","journal-title":"Intern. Emerg. Med."},{"key":"474_CR131","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691\u20132697 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"474_CR132","first-page":"556","volume":"132","author":"AM Li","year":"2018","unstructured":"Li, A. M. et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia [abstract]. Blood 132 (Suppl. 1), 556 (2018).","journal-title":"Blood"},{"key":"474_CR133","doi-asserted-by":"crossref","first-page":"4S115","DOI":"10.14735\/amko20154S115","volume":"28","author":"V Bajciova","year":"2015","unstructured":"Bajciova, V. Therapeutic effect and tolerance of ipilimumam in metastatic malignant melanoma in children \u2013 a case report. Klin. Onkol. 28, 4S115\u20134S120 (2015).","journal-title":"Klin. Onkol."},{"key":"474_CR134","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11060-016-2190-1","volume":"129","author":"DT Blumenthal","year":"2016","unstructured":"Blumenthal, D. T. et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J. Neurooncol 129, 453\u2013460 (2016).","journal-title":"J. Neurooncol"},{"key":"474_CR135","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206\u20132211 (2016).","journal-title":"J. Clin. Oncol."},{"key":"474_CR136","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1097\/MPH.0000000000000703","volume":"39","author":"AE Foran","year":"2017","unstructured":"Foran, A. E., Nadel, H. R., Lee, A. F., Savage, K. J. & Deyell, R. J. Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J. Pediatr. Hematol. Oncol. 39, e263\u2013e266 (2017).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"474_CR137","volume":"64","author":"AT Shad","year":"2017","unstructured":"Shad, A. T. et al. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr. Blood Cancer 64, e26257 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"474_CR138","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3171\/2016.8.PEDS16326","volume":"19","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J. Neurosurg. Pediatr. 19, 249\u2013253 (2017).","journal-title":"J. Neurosurg. Pediatr."},{"key":"474_CR139","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"474_CR140","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092\u20132099 (2015).","journal-title":"J. Clin. Oncol."},{"key":"474_CR141","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","volume":"6","author":"S Trinh","year":"2019","unstructured":"Trinh, S., Le, A., Gowani, S. & La-Beck, N. M. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac. J. Oncol. Nurs. 6, 154\u2013160 (2019).","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"474_CR142","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1006\/jsre.2000.5909","volume":"91","author":"EH Livingston","year":"2000","unstructured":"Livingston, E. H. & Lee, S. Percentage of burned body surface area determination in obese and nonobese patients. J. Surg. Res. 91, 106\u2013110 (2000).","journal-title":"J. Surg. Res."},{"key":"474_CR143","first-page":"1109","volume":"86","author":"P Ham","year":"2012","unstructured":"Ham, P. & Allen, C. Adolescent health screening and counseling. Am. Fam. Phys. 86, 1109\u20131116 (2012).","journal-title":"Am. Fam. Phys."},{"key":"474_CR144","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"Clotman, K., Janssens, K., Specenier, P., Weets, I. & De Block, C. E. M. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 3144\u20133154 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"474_CR145","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli, A. M. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67, 1471\u20131480 (2018).","journal-title":"Diabetes"},{"key":"474_CR146","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.resinv.2020.05.008","volume":"58","author":"K Sakamoto","year":"2020","unstructured":"Sakamoto, K., Fukihara, J., Morise, M. & Hashimoto, N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respir. Investig. 58, 305\u2013319 (2020).","journal-title":"Respir. Investig."},{"key":"474_CR147","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo, J. et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J. Clin. Oncol. 35, 709\u2013717 (2017).","journal-title":"J. Clin. Oncol."},{"key":"474_CR148","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(18)30172-3","volume":"6","author":"S Rashdan","year":"2018","unstructured":"Rashdan, S., Minna, J. D. & Gerber, D. E. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir. Med. 6, 472\u2013478 (2018).","journal-title":"Lancet Respir. Med."},{"key":"474_CR149","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja, A. KDIGO clinical practice guideline for acute kidney injury. Nephron. Clin. Pract. 120, c179\u2013c184 (2012).","journal-title":"Nephron. Clin. Pract."},{"key":"474_CR150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.34067\/KID.0000852019","volume":"1","author":"S Gupta","year":"2020","unstructured":"Gupta, S., Cortazar, F. B., Riella, L. V. & Leaf, D. E. Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360 1, 130\u2013140 (2020).","journal-title":"Kidney360"},{"key":"474_CR151","first-page":"1546","volume":"9","author":"Y Ma","year":"2019","unstructured":"Ma, Y., Wang, Q., Dong, Q., Zhan, L. & Zhang, J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am. J. Cancer Res. 9, 1546\u20131553 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"474_CR152","doi-asserted-by":"crossref","first-page":"S1564","DOI":"10.21037\/jtd.2018.01.131","volume":"10","author":"R Ferrara","year":"2018","unstructured":"Ferrara, R. et al. Do immune checkpoint inhibitors need new studies methodology? J. Thorac. Dis. 10, S1564\u2013S1580 (2018).","journal-title":"J. Thorac. Dis."},{"key":"474_CR153","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"474_CR154","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","volume":"19","author":"M Nishino","year":"2013","unstructured":"Nishino, M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936\u20133943 (2013).","journal-title":"Clin. Cancer Res."},{"key":"474_CR155","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-18-3206","volume":"25","author":"J-C Pignon","year":"2019","unstructured":"Pignon, J.-C. et al. irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial. Clin. Cancer Res. 25, 2174\u20132184 (2019).","journal-title":"Clin. Cancer Res."},{"key":"474_CR156","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"474_CR157","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"474_CR158","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 4, 717\u2013721 (2018).","journal-title":"JAMA Oncol."},{"key":"474_CR159","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."},{"key":"474_CR160","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Di Giacomo","year":"2009","unstructured":"Di Giacomo, A. M. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother. 58, 1297\u20131306 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"474_CR161","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.jtho.2018.12.024","volume":"14","author":"K Masuhiro","year":"2019","unstructured":"Masuhiro, K., Shiroyama, T., Nagatomo, I. & Kumanogoh, A. Unique case of pseudoprogression manifesting as lung cavitation after pembrolizumab treatment. J. Thorac. Oncol. 14, e108\u2013e109 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"474_CR162","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2016.10.014","volume":"102","author":"J Tanizaki","year":"2016","unstructured":"Tanizaki, J. et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer 102, 44\u201348 (2016).","journal-title":"Lung Cancer"},{"key":"474_CR163","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2017.08.020","volume":"113","author":"MJ Hochmair","year":"2017","unstructured":"Hochmair, M. J., Schwab, S., Burghuber, O. C., Krenbek, D. & Prosch, H. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer 113, 4\u20136 (2017).","journal-title":"Lung Cancer"},{"key":"474_CR164","doi-asserted-by":"crossref","first-page":"100514","DOI":"10.1016\/j.eclinm.2020.100514","volume":"26","author":"MA Kohorst","year":"2020","unstructured":"Kohorst, M. A. et al. Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. EClinicalMedicine 26, 100514 (2020).","journal-title":"EClinicalMedicine"},{"key":"474_CR165","volume":"16","author":"J Kim","year":"2016","unstructured":"Kim, J., Park, J. H. & Shin, S. Effectiveness of simulation-based nursing education depending on fidelity: a meta-analysis. BMC Med. Educ. 16, 152 (2016).","journal-title":"BMC Med. Educ."},{"key":"474_CR166","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/msj.20127","volume":"76","author":"Y Okuda","year":"2009","unstructured":"Okuda, Y. et al. The utility of simulation in medical education: what is the evidence? Mt. Sinai J. Med. 76, 330\u2013343 (2009).","journal-title":"Mt. Sinai J. Med."},{"key":"474_CR167","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1164\/rccm.201810-1945ED","volume":"200","author":"E Azoulay","year":"2019","unstructured":"Azoulay, E., Shimabukuro-Vornhagen, A., Darmon, M. & von Bergwelt-Baildon, M. Critical care management of chimeric antigen receptor T cell-related toxicity. Be aware and prepared. Am. J. Respir. Crit. Care Med. 200, 20\u201323 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"474_CR168","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1164\/rccm.202002-0286LE","volume":"202","author":"r","year":"2020","unstructured":"r ICU resource utilization in critically ill patients following chimeric antigen receptor T-cell therapy. Am. J. Respir Crit. Care Med. 202, 1184\u20131187 (2020).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"474_CR169","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"G Redelman-Sidi","year":"2018","unstructured":"Redelman-Sidi, G. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin. Microbiol. Infect. 24, S95\u2013S107 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"474_CR170","volume":"138","author":"HD Davies","year":"2016","unstructured":"Davies, H. D. & Committee on Infectious Diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics 138, e20161209 (2016).","journal-title":"Pediatrics"},{"key":"474_CR171","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill, J. A. & Seo, S. K. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136, 925\u2013935 (2020).","journal-title":"Blood"},{"key":"474_CR172","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/cid\/ciy1025","volume":"69","author":"JA Fishman","year":"2019","unstructured":"Fishman, J. A., Hogan, J. I. & Maus, M. V. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin. Infect. Dis. 69, 909\u2013920 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"474_CR173","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2019","unstructured":"Yakoub-Agha, I. et al. Management of adults and children undergoing CAR T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105, 297\u2013316 (2019).","journal-title":"Haematologica"},{"key":"474_CR174","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2008.02934.x","volume":"127","author":"DF Kelly","year":"2009","unstructured":"Kelly, D. F. et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 127, 134\u2013143 (2009).","journal-title":"Immunology"},{"key":"474_CR175","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez, E. E. et al. Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy Clin. Immunol. 139, S1\u2013S46 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"474_CR176","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn, M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transpl. 15, 1143\u20131238 (2009).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR177","first-page":"111","volume":"68","author":"Y Hu","year":"2020","unstructured":"Hu, Y. et al. CAR T-cell treatment during the COVID-19 pandemic: management strategies and challenges. Curr. Res. Transl. Med. 68, 111\u2013118 (2020).","journal-title":"Curr. Res. Transl. Med."},{"key":"474_CR178","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jpids\/piaa088","volume":"9","author":"G Bisogno","year":"2020","unstructured":"Bisogno, G. et al. Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. J. Pediatric Infect. Dis. Soc. 9, 530\u2013534 (2020).","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"474_CR179","doi-asserted-by":"crossref","first-page":"102903","DOI":"10.1016\/j.ebiom.2020.102903","volume":"59","author":"A Mohammadi","year":"2020","unstructured":"Mohammadi, A., Esmaeilzadeh, E., Li, Y., Bosch, R. J. & Li, J. Z. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. EbioMedicine 59, 102903 (2020).","journal-title":"EbioMedicine"},{"key":"474_CR180","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou, X., Zhou, J. & Zhao, J. Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. BMC Infect. Dis. 20, 500 (2020).","journal-title":"BMC Infect. Dis."},{"key":"474_CR181","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","volume":"26","author":"J Ruark","year":"2020","unstructured":"Ruark, J. et al. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol. Blood Marrow Transpl. 26, 34\u201343 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"474_CR182","doi-asserted-by":"crossref","first-page":"r","DOI":"10.1016\/j.leukres.2011.06.021","volume":"35","author":"HE Broome","year":"2011","unstructured":"Broome, H. E., Rassenti, L. Z., Wang, H. Y., Meyer, L. M. & Kipps, T. J. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk. Res. 35, r\u20131394 (2011).","journal-title":"Leuk. Res."},{"key":"474_CR183","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 24, 6175\u20136184 (2018).","journal-title":"Clin. Cancer Res."},{"key":"474_CR184","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2010.09.021","volume":"231","author":"R Weissert","year":"2011","unstructured":"Weissert, R. Progressive multifocal leukoencephalopathy. J. Neuroimmunol. 231, 73\u201377 (2011).","journal-title":"J. Neuroimmunol."},{"key":"474_CR185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","volume":"18","author":"P Brown","year":"2020","unstructured":"Brown, P. et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 18, 81\u2013112 (2020).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"474_CR186","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","volume":"128","author":"SL Maude","year":"2016","unstructured":"Maude, S. L. et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia [abstract]. Blood. 128, 217 (2016).","journal-title":"Blood."},{"key":"474_CR187","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","volume":"34","author":"SL Maude","year":"2016","unstructured":"Maude, S. L. et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL [abstract]. J. Clin. Oncol. 34, 3011 (2016).","journal-title":"J. Clin. Oncol."},{"key":"474_CR188","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/cancers12020303","volume":"12","author":"F Lanza","year":"2020","unstructured":"Lanza, F. et al. CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers 12, 303 (2020).","journal-title":"Cancers"},{"key":"474_CR189","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"474_CR190","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938\u20131950 (2020).","journal-title":"J. Clin. Oncol."},{"key":"474_CR191","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019. Nat. Rev. Clin. Oncol. 15, 218 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"474_CR192","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","volume":"3","author":"V Dufner","year":"2019","unstructured":"Dufner, V. et al. Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 3, 2491\u20132498 (2019).","journal-title":"Blood Adv."},{"key":"474_CR193","first-page":"352","volume":"79","author":"CC Lund","year":"1944","unstructured":"Lund, C. C. The estimation of areas of burns. Surg. Gynecol. Obste 79, 352\u2013358 (1944).","journal-title":"Surg. Gynecol. Obste"}],"updated-by":[{"DOI":"10.1038\/s41571-021-00497-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00474-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00474-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00474-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:49:00Z","timestamp":1733957340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00474-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":193,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1038\/s41571-021-00474-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41571-021-00497-x","asserted-by":"object"}]},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"13 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-021-00497-x","URL":"https:\/\/doi.org\/10.1038\/s41571-021-00497-x","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.G. has served on the advisory board for Janssen and Legend Biotech. A relative of J.B.G. is a consultant to Acceleron and Celgene. K.R. and E.J.S. have a licence agreement with Takeda. E.J.S. has served on the advisory boards of Adaptimmune, Axio, Bayer, Celgene, Magenta, Mesoblast and Novartis. K.M.M. serves as a site investigator for, receives research funding from and has served as a medical consultant for Atara Biotherapeutics, and has received research and medical education funds from and served as a medical consultant for Jazz Pharmaceuticals. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}